GSK plc (FRA:GS71)
Germany
· Delayed Price · Currency is EUR | Market Cap | 100.52B |
| Revenue (ttm) | 37.45B |
| Net Income (ttm) | 6.55B |
| Shares Out | n/a |
| EPS (ttm) | 1.59 |
| PE Ratio | 15.34 |
| Forward PE | 12.36 |
| Dividend | 0.76 (3.07%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,714 |
| Average Volume | 1,559 |
| Open | 24.55 |
| Previous Close | 24.79 |
| Day's Range | 24.55 - 24.99 |
| 52-Week Range | 14.68 - 26.02 |
| Beta | n/a |
| RSI | 60.23 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK to buy 35Pharma for $950 million
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announc...
Frontier Biotechnologies strikes up to $1 billion deal with GSK
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an ...
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a ...
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT ...
3 International Stocks to Buy for 2026
Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strate...
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK's Specialty Medicines Drive Solid Results
The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
GSK forecasts slower sales growth in 2026
GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries f...
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK
The FTSE 100 Index continued its rally this week and was hovering near its all-time high as market participants reacted to the key earnings by some American companies and Lloyds Bank. It was trading ...
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
PHILADELPHIA--(BUSINESS WIRE)-- #DiseaseEducation--GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026.
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a def...
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and lo...
GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of G...
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK Still Has Room To Run Despite Vaccine Cyclicality
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...